Sign in

CIK 0000939767

  • Large accelerated filer

EXELIXIS, INC.

Sign in to watch
Ticker
EXEL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Jan 1
Incorporated
DE
Entity type
Operating
EIN
043257395
Phone
+1 650-837-7000
Business address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502
Former names
EXELIXIS INC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 100 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2023-04-05 Hessekiel Jeffrey EVP, General Counsel & Sec Option exercise 10b5-1 +13,930 $14.74 $205K 621,365
2023-04-05 Hessekiel Jeffrey EVP, General Counsel & Sec Sale 10b5-1 −38,930 $20.01 $779K 582,435
2023-04-05 Hessekiel Jeffrey EVP, General Counsel & Sec Option exercise · Option (right to buy) 10b5-1 −13,930 55,710
2023-04-03 Hessekiel Jeffrey EVP, General Counsel & Sec Grant or award 10b5-1 +79,719 607,435
2023-04-03 MORRISSEY MICHAEL President and CEO Grant or award +313,185 642,318
2023-04-03 Aftab Dana CSO/EVP Disc & Trans Research Grant or award +68,331 419,803
2023-04-03 Senner Christopher J. EVP and CFO Grant or award +85,414 590,077
2023-04-03 Goodman Vicki L EVP, Prod Dev & Med Aff &CMO Grant or award +82,566 307,654
2023-04-03 Haley Patrick J. EVP, Commercial Grant or award +79,719 332,577
2023-03-10 WYSZOMIERSKI JACK L Director Option exercise +40,000 $6.30 $252K 332,767
2023-03-10 WYSZOMIERSKI JACK L Director Sale −15,300 $16.61 $254K 317,467
2023-03-10 WYSZOMIERSKI JACK L Director Option exercise · Option (right to buy) −40,000 0
2023-03-01 Hessekiel Jeffrey EVP, General Counsel & Sec Option exercise +27,860 $14.74 $411K 605,576
2023-03-01 Hessekiel Jeffrey EVP, General Counsel & Sec Sale −77,860 $17.13 $1.3M 527,716
2023-03-01 Hessekiel Jeffrey EVP, General Counsel & Sec Option exercise · Option (right to buy) −27,860 69,640
2023-02-28 Aftab Dana CSO/EVP Disc & Trans Research Option exercise +82,490 $14.74 $1.2M 433,962
2023-02-28 Aftab Dana CSO/EVP Disc & Trans Research Sale −82,490 $17.50 $1.4M 351,472
2023-02-28 Aftab Dana CSO/EVP Disc & Trans Research Option exercise · Option (right to buy) −82,490 0
2023-02-27 Aftab Dana CSO/EVP Disc & Trans Research Option exercise +10 $14.74 $147 351,482
2023-02-27 Aftab Dana CSO/EVP Disc & Trans Research Sale −10 $17.50 $175 351,472

Page 21 of 29 · 580 trades